Frontiers

upfrontFall12

Cancer Research at a Land Grant University On July 2, the United States celebrated the 150th anniversary of one of President Abraham Lincoln's most significant legacies: the Morrill Land-Grant College Act. It led to the ...[Read more]
Published: Oct-31-12 | 0  Comment | 0  Link to this post

Frontline

Harnessing Ohio State's Innovative Engine The OSUCCC – James and the University are preparing an initiative to methodically develop cancer therapeutics By TIMOTHY WRIGHT, director Drug Development Institute After a long career in the pharmac ...[Read more]
Published: Oct-31-12 | 1  Comment | 0  Link to this post

BreakthroughFall12

AML INSIGHT microRNA Prognostic Marker Identified in Acute Leukemia CLARA D. BLOOMFIELD, MD, Distinguished University Professor, the William Greenville Pace III Endowed Chair in Cancer Research, and cancer scholar/s ...[Read more]
Published: Oct-31-12 | 1  Comment | 0  Link to this post

Of Note Fall 12

AWARDS AND HONORS CARLO CROCE, MD, chair of the Department of Molecular Virology, Immunology and Medical Genetics, holder of the John W. Wolfe Chair in Human Cancer Genetics and director of Human Cancer Gene ...[Read more]
Published: Oct-31-12 | 1  Comment | 0  Link to this post

A Mutual Exchange

A MUTUAL EXCHANGE Ohio State researchers are integrating studies of anticancer drugs for canines into the development of drugs for humans for the benefit of both BY BOB HECKER Hundreds of cancer patients are benef ...[Read more]
Published: Oct-31-12 | 2  Comments | 0  Link to this post

80 is the new 50

80 is the new 50 Research supports more aggressive treatment for colon cancer in older patients By KENDALL POWELL The patient was an 86-year-old woman, and surgeon Mark Bloomston, MD, carefully considered whether to remo ...[Read more]
Published: Oct-31-12 | 2  Comments | 0  Link to this post

Campus Connections

GREGORY B. LESINSKI, PhD, MPH, Tumor Immunologist CAMPUS CONNECTIONS OSUCCC – James researchers from disparate Ohio State colleges link up to undertake novel interdisciplinary research that can have striking clinical ...[Read more]
Published: Oct-31-12 | 2  Comments | 0  Link to this post

Bench To Bedside Fall 12

A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer HYPOTHESIS: Combining a DNA-damaging agent such as carboplatin with the PARP inhibitor veliparib will improve outcom ...[Read more]
Published: Oct-31-12 | 1  Comment | 0  Link to this post

 Next >>